HEALTHCARE RESOURCE UTILIZATION ASSOCIATED WITH POLYMYALGIA RHEUMATICA IN THE UNITED STATES
Author(s)
Punekar R1, LaFontaine P2, Stone JH3
1Sanofi, Cambridge, MA, USA, 2Sanofi, Morristown, NJ, USA, 3Harvard Medical School, Boston, MA, USA
Presentation Documents
BACKGROUND: Polymyalgia rheumatica (PMR) is a common rheumatologic disorder. Current treatment options are limited to long-term glucocorticoid (GC) use, putting patients at risk for GC-related complications. OBJECTIVES: To compare the healthcare resource utilization (HCRU) of PMR patients with the general population (GnP). METHODS: Data was obtained from Optum’s de-identified Clinformatics® Data Mart Database between 01/01/2006–06/30/2018 (study period). Patients with ≥1 inpatient or ≥2 outpatient claims (≥30 days apart) with PMR-related diagnosis codes between 01/01/2007–06/30/2017 (patient identification period) were included in the PMR cohort; the service date of first PMR medical claim was set as their index date. Patients with ≥1 medical claim for rheumatoid arthritis (RA) or giant cell arteritis (GCA) codes during the study period were excluded. Patients without any medical claims for RA, GCA, or PMR during the study period were included in the GnP cohort; 12 months from the start of continuous health plan enrollment was set as their index date. Patients in both cohorts were required to be ≥50 years (on the index date) with ≥12 months continuous health plan enrollment before and after the index date. PMR and GnP cohorts were 1:1 propensity score-matched. Statistical analyses (t-test/Wilcoxon Sum Rank test, Chi-square/Fisher’s exact tests) compared HCRU between the matched cohorts. RESULTS: Among 16,865 patients in each matched cohort, the majority were female (64.6%) with mean (SD) age 74.4 (8.4) years and mean (SD) Elixhauser comorbidity score 2.8 (2.4). During 1-year follow-up period, proportions of patients with ≥1 hospitalizations (23.3% vs 17.8%), emergency room visits (35.1% vs 28.9%), physician visits (96.6% vs 89.5%), and rheumatologist visits (31.5% vs 2.2%) were higher (P<0.0001) among PMR patients than the controls. CONCLUSIONS: Overall HCRU in PMR patients was higher than the matched and highly comorbid GnP cohort.
Conference/Value in Health Info
2020-05, ISPOR 2020, Orlando, FL, USA
Value in Health, Volume 23, Issue 5, S1 (May 2020)
Code
PMS13
Topic
Economic Evaluation, Health Service Delivery & Process of Care
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis, Disease Management, Prescribing Behavior, Treatment Patterns and Guidelines
Disease
Musculoskeletal Disorders